DBD Search
Grant R. Zimmermann
Managing Director of Business Development, Blavatnik Biomedical Accelerator
Displaying: 41 - 50 of 67 Results
Invention
Targeted inhibition of the SREBP-mediator interaction as a novel therapeutic
While most therapeutic approaches aimed at altering gene expression programs target upstream signaling pathways or nuclear translocation checkpoints, Scientists at the Wagner lab have provided mechanistic insights supporting an alternative approach,…
Investigators
- Gerhard Wagner
- Anders M. Naar
- Haribabu Arthanari
Invention
Mass spectrometry-based in vitro kinome activity assay
This technology is a new generation, high-throughput assay to quantitatively assess the activity of the kinome in a variety of samples. Cocktails of synthetic peptides are combined with a sample of interest and phosphorylated by kinases in the…
Investigators
- Steven P. Gygi
- Judit Villen
- Kazuishi Kubota
- Yong Yu
Invention
Inhibitors of protein-processivity factor
Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions,…
Investigators
- Donald M. Coen
- James M. Hogle
- Harmon Zuccola
- Kristie Grove Bridges
- Carl Elkin
- Scott R. Lokey
Invention
A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination
HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…
Investigators
- Stephen C. Harrison
- Gary H. Frey
- Bing Chen
Invention
Method for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites
A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an FRT site). The invention in particular discloses the…
Investigators
- Susan M. Dymecki
- A. Francis Stewart
Invention
Metabolic labeling and direct imaging of choline-containing phospholipids in vivo
A functional analog of a metabolic phospholipid precursor has been devised that, when contacted with cells, becomes incorporated into a cells endogenous phospholipids through cellular metabolic processes. The resulting phospholipids contain a moiety…
Investigators
- Adrian Salic
Invention
anti-MARCO monoclonal antibody
The monoclonal antibody recognizes the Macrophage Receptor with Collagenous structure (MARCO). The scavenger receptors (SRs) expressed by macrophages are thought to play an important role in the immune response against bacteria by mediating binding…
Investigators
- Lester Kobzik
- Aiyappa M. Palecanda
Invention
Homozygous IKKepsilon knockout mouse as an animal model for influenza virus infection
Homozygous IKKepsilon (inhibitor of kappaB kinase epsilon) mutant mice are used as animal models for influenza virus infection. Homozygous deletion results in a complete loss of the endogenous kinase function in lung, spleen, and embryonic…
Investigators
- Thomas Maniatis
- Benjamin R. tenOever
Research Tool
ACTB:FLPe B6N Transgenic Mice
This transgenic strain expresses a variant of the Saccharomyces cerevisiae FLP1 recombinase gene under the direction of the human ACTB promoter. The FLPe recombinase variant exhibits enhanced thermostability with recombination activity being…
Investigators
- Susan M. Dymecki
Research Tool
Top2beta Flox2 Targeted Mutation Mice
These mice possess loxP sites flanking the 3 exons encoding the active-site tyrosyl residue of the targeted gene. Mice that are homozygous for this allele are viable, fertile, normal in size and do not display any gross physical or behavioral…
Investigators
- James Wang